GlassScriptPhysician profile
Jose M Rodriguez
NPI 1043228661
$1,066.12
in general payments reported to CMS, 2019-2025
23 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $11.23 · 2021: $48.81 · 2022: $139 · 2023: $138 · 2024: $192 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $656.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $135.43 | 2019-2025 | |
| Abbott Laboratories | $119.68 | 2025 | Freestyle Libre 3 |
| Abbvie INC. | $103.00 | 2022-2025 | Ubrelvy |
| Novo Nordisk INC | $102.00 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $81.89 | 2019-2021 | |
| Lilly USA, LLC | $73.70 | 2024-2025 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $50.73 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $48.41 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $48.07 | 2022 | |
| Scilex Pharmaceuticals INC. | $36.30 | 2022 | |
| Glaxosmithkline, LLC. | $33.00 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $32.53 | 2019 | |
| Sanofi Pasteur INC. | $29.12 | 2023 | |
| Medtronic Vascular, INC. | $28.98 | 2019 | |
| Hologic Sales and Service, LLC | $25.26 | 2024 | Aptima |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $23.97 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $20.84 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $15.91 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $14.88 | 2023 | Farxiga |
| Biohaven Pharmaceuticals, INC. | $14.28 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.11 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.03 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.